3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
3
Mucositis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Febrile Neutropenia
2
Polycystic Ovary Syndrome
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Inflammation
1
Hematologic Neoplasms
1
Early Stage Triple Negative ER Low Breast Cancer
1
Disease Progression
1
Cytokine Release Syndrome
1
Colorectal Neoplasms
1
Burkitt Lymphoma
1
Arthritis, Rheumatoid
1
Interventions
Metformin
12
Clomiphene
6
Inositol
3
maltodextrin
2
artenimol
2
Thioctic Acid
2
Tablets
2
Sugars
2
Spironolactone
2
Pioglitazone
2
Orlistat
2
Contraceptives, Oral
2
Cholecalciferol
2
salicylsalicylic acid
1
licogliflozin
1
follitropin alfa
1
elagolix
1
Vitamin E
1
Vitamin D
1
Tooth Exfoliation
1
Sodium Salicylate
1
Root Planing
1
Resveratrol
1
Quercetin
1
Pentoxifylline
1
Ovulation Induction
1
Linseed Oil
1
Leuprolide
1
Letrozole
1
Inulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Polycystic Ovary Syndrome
×
Interleukin 1 Receptor Antagonist Protein
×
Clear all
NCT03578497
2021-01-27
FertIL
University Hospital, Basel, Switzerland
Phase 2
Completed
18 enrolled